Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis.

What It Covers

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a meta-analysis.

The effect of GH replacement on bone mineral density (BMD) in adults with GH deficiency (GHD) is uncertain.

The researchers carried out a systematic review of randomized trials that compared GH to no active treatment, with BMD as an outcome.

Who the Included Studies Covered

PubMed indexes the participants as adults, both men and women.

How the Review Was Done

The researchers searched electronic databases to identify articles, abstracts and conference proceedings to March 2002.

The researchers also checked reference lists in included studies and expert reviews.

Two reviewers independently extracted the data on study design and change in BMD.

The results of individual trials were combined by fixed effects model meta-analysis using weighted mean difference (WMD) of change in BMD at the lumbar spine (their primary outcome) and other sites.

What Was Measured

The researchers carried out a systematic review of randomized trials that compared GH to no active treatment, with BMD as an outcome.

PubMed files the paper under topics including Bone Density, Databases, Bibliographic, Fractures, Bone, Growth Hormone, Lumbar Vertebrae and Randomized Controlled Trials as Topic.

What This Means in Plain Language

This is a meta-analysis of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2004 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.